Should we use combination therapy for all advanced renal cell carcinoma?

Affiliations

¹ Medical Oncology Unit, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, Milan 20133, Italy. Electronic address: giuseppe.procopio@istitutotumori.mi.it.
² Medical Oncology Unit, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, Milan 20133, Italy.

Comment

Giuseppe Procopio et al. Lancet Oncol. 2019 Oct.

. 2019 Oct;20(10):1331-1332.

doi: 10.1016/S1470-2045(19)30518-2. Epub 2019 Aug 16.

¹ Medical Oncology Unit, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, Milan 20133, Italy. Electronic address: giuseppe.procopio@istitutotumori.mi.it.
² Medical Oncology Unit, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, Milan 20133, Italy.

No abstract available

Comment on

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Motzer RJ, et al. Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Lancet Oncol. 2019. PMID: 31427204 Free PMC article. Clinical Trial.